ZEVRA THERAPEUTICS, INC.
ZEVRA THERAPEUTICS, INC. (ZVRA): 7 pipeline candidates · 1 upcoming catalyst · ~24 mo cash runway. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
24.3 months
D/E 0.35 · 2% dilution
Lead: Approved
7 candidates
1 upcoming, next in ~1710d
0 buys · 9 sells (180d)
A transparent, data-derived signal for ZEVRA THERAPEUTICS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$741.9M
Cash
$95.6M
Quarterly Burn
$25.2M
Runway
24.3 mo
Revenue
$36.2M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| apadaz | Approved |
| azstarys | Approved |
| celiprolol | Phase 3 |
| kp1077 | Phase 3 |
| miplyffa | Approved |
| miplyffa capsules as an orally delivered treatment | Approved |
| olpruva | Approved |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
145
Total value held
$369.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,938,656 | $46.0M |
| blackrock, inc. | 4,456,476 | $41.5M |
| fmr llc | 3,211,877 | $29.9M |
| caption management, llc | 2,353,136 | $21.9M |
| state street corp | 1,561,569 | $14.6M |
| geode capital management, llc | 1,371,857 | $12.8M |
| morgan stanley | 1,192,262 | $11.1M |
| legal & general group plc | 1,163,090 | $10.8M |
| point72 asset management, l.p. | 1,157,131 | $10.8M |
| royce & associates lp | 988,674 | $9.2M |
Showing top 10 of 145 institutional holders of ZEVRA THERAPEUTICS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ZEVRA THERAPEUTICS, INC.'s pipeline?
ZEVRA THERAPEUTICS, INC. (ZVRA) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ZEVRA THERAPEUTICS, INC.'s lead drug candidate?
ZEVRA THERAPEUTICS, INC.'s most advanced tracked candidate is apadaz (Approved).
What is ZEVRA THERAPEUTICS, INC.'s next catalyst?
ZEVRA THERAPEUTICS, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: APADAZ" — expected February 22, 2031.
What is ZEVRA THERAPEUTICS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ZEVRA THERAPEUTICS, INC. has approximately 24.3 months of cash runway.
What is ZEVRA THERAPEUTICS, INC.'s market capitalization?
ZEVRA THERAPEUTICS, INC.'s market capitalization is approximately $741.9M.
Get the full picture on ZEVRA THERAPEUTICS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.